Drug Discovery & Development
CRISPR phage offers precision medicine tool to fight bacterial infections
In an attempt to combat bacterial infections, Locus Biosciences is developing bacteriophage therapies that deliver CRISPR-Cas3 machinery directly to specific, targeted pathogens to obliterate them. Locus CEO Paul Garofolo discusses the company's technology and recent updates with The ScienceBoard.net.  Discuss
Oxford/AstraZeneca COVID-19 vaccine strongly efficacious in older adults
Similar safety and immunogenicity profiles were observed in adults and older adults who received the Oxford/AstraZeneca SARS-CoV-2 vaccine candidate, ChAdOx1 nCoV-19, according to data from the phase II clinical trial. The findings were published in the Lancet on November 18.  Discuss
Pfizer, BioNTech just days away from applying for EUA for COVID-19 vaccine
Pfizer and BioNTech have passed another milestone in their effort to deliver a vaccine for the SARS-CoV-2 virus. The companies on November 18 reported that their BNT162b2 vaccine candidate has met safety milestones and that they plan to apply for an emergency use authorization (EUA) from the U.S. Food and Drug Administration for the product in the coming days.  Discuss
Moderna reports 94.5% efficacy for COVID-19 vaccine
A COVID-19 vaccine under development by Moderna had 94.5% efficacy in a phase III clinical trial, according to an independent data safety monitoring board that notified the company of the results. The news builds on positive sentiment that a solution to the COVID-19 pandemic could be around the corner.  Discuss
Can vaccine resistance be predicted with test samples?
The likelihood of SARS-CoV-2 developing resistance to COVID-19 vaccines currently under development can be determined using repurposed blood and nasal test samples that are already being collected as part of clinical trials, according to Pennsylvania State University researchers. The perspective piece was published in PLOS Biology on November 9.  Discuss
If successful, COVID-19 vaccines could be worth $27B
Vaccines are considered one of the most effective public health measures preventing diseases in the modern world. They could also be very profitable endeavors, according to a new report from Kalorama Information, which estimates the market for COVID-19 vaccines could be as high as $27 billion.  Discuss
Effectiveness of COVID-19 vaccines will rely on public trust
No matter how effective upcoming COVID-19 vaccines are, their ultimate success in combating the pandemic will depend on how much the public trusts the safety and efficacy of the products. That's according to a panel of physicians and scientists who discussed COVID-19 vaccine trials in a briefing on October 29.  Discuss
Validating drug repurposing workflows may help identify new COVID-19 treatments
A research team has strengthened COVID-19 drug repurposing workflows through independent in vitro validation followed by clinical pharmacology data assessments, with the goal of launching clinical studies of currently approved drugs. The protocol was published in ACS Pharmacology & Translational Science on October 14.  Discuss
FDA issues guidance on submitting EUA requests for COVID-19 vaccines
The U.S. Food and Drug Administration (FDA) on October 6 issued a new guidance with recommendations for developers of COVID-19 vaccines regarding the scientific data and information that would be required to support emergency use authorization (EUA) for the products.  Discuss
Is 'bespoke' therapy the future of genomic medicine?
Gene therapies hold extremely exciting promise for meeting the unmet needs of many individuals with genetic diseases, as discussed in a session of the second annual American Society of Gene & Cell Therapy Policy Summit on September 24.  Discuss
Conferences
Festival of Genomics & Biodata
January 28-29, 2021
London, Greater London United Kingdom
Lab of the Future USA
May 11-12, 2021
Boston, Massachusetts United States
Connect
Science Advisory Board on LinkedIn
Science Advisory Board on Facebook
Science Advisory Board on Twitter